nav-left cat-right
cat-right

World AntiMicrobial Resistance Congress USA 2015 O...

The World AntiMicrobial Resistance Congress USA gathers key stakeholders from government, funding agencies, pharma, academia and payers to discuss the urgent need for new antibiotics. President Obama has outlined his 5-year action plan to fight AMR and is seeking to double the AMR funding to $1.2B, but the bigger challenge is how to deliver these actions. This 2-day conference presents solutions through key notes, case study...

GlaxoSmithKline joins a $115M antibiotics developm...

Resistance to antibacterials is fast becoming one of the most urgent public health problems, especially since the pipeline for new antibiotics largely has dried up after Big Pharma’s retreat from the field in recent years. To help combat growing antimicrobial resistance, more than 30 European universities, research institutions and drug companies are joining together to launch a 6-year, €85 million ($115.5 million)...

Honey fights antibiotic resistance

Honey, that delectable condiment for breads and fruits, could be one sweet solution to the serious, ever-growing problem of bacterial resistance to antibiotics, researchers said. Medical professionals sometimes use honey successfully as a topical dressing, but it could play a larger role in fighting infections, the researchers predicted. “The unique property of honey lies in its ability to fight infection on multiple...

University of Notre Dame team IDs new class of ant...

Researchers from the University of Notre Dame may have discovered a new class of antibiotics to combat deadly bacteria like methicillin-resistant Staphylococcus aureus, or MRSA, which pose serious threats to public health. Led by Mayland Chang and Shahriar Mobashery, investigators identified the new class of antibiotics, called oxadiazoles, by using virtual screening to sift through 1.2 million compounds. Researchers found...

Bill would fast-track promising antibiotics for FD...

The antibiotics arena hasn’t proved lucrative enough for Big Pharma, leading to a mass exodus from the field in recent years. But pharma companies may have a reason to get back in the antibiotics game. A group of bipartisan members in the House of Representatives introduced a bill late Thursday that aims to combat the growing threat of so-called “superbugs” by essentially providing a fast-track route to FDA...

Immune Pharmaceuticals Merges with EpiCept

Immune Pharmaceuticals and EpiCept have agreed to merge. The combined company, to be named Immune Pharmaceuticals, will be primarily focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. Immune Pharmaceuticals is an Israel- and U.S.-based biopharmaceutical company focused on the development of next-generation antibody therapeutics addressing unmet...
Page 1 of 212